FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR4 Overexpression1
Dovitinib +

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

FGFR4 N535K1
FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Rhabdomyosarcoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID8906 FGFR4 tyrosine kinase domain mutations were found among 7 of 94 (7.5%) primary human RMS tumors. The mutants K535 and E550 increased autophosphorylation, Stat3 signaling, tumor proliferation, and meta… (full text at CIViC) PMID 19809159 · Taylor et al., 2009 · Open in CIViC	civic

FGFR4 V550E1
FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Rhabdomyosarcoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID8907 FGFR4 tyrosine kinase domain mutations were found among 7 of 94 (7.5%) primary human RMS tumors. The mutants K535 and E550 increased autophosphorylation, Stat3 signaling, tumor proliferation, and meta… (full text at CIViC) PMID 19809159 · Taylor et al., 2009 · Open in CIViC	civic

FGFR1 Expression1
Fexagratinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 + InfigratinibSubstitutes	Sarcoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID2915 Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, … (full text at CIViC) PMID 27535980 · Chudasama et al., 2017 · Open in CIViC	civic